Dysphagia in Neurodegenerative Disease: Focus on ALS and Parkinson’s Disease

Presenter: Debra Suiter, Ph.D., CCC-SLP, BCS-S

Moderated by: Amy Natho, M.S., CCC-SLP, CEU Administrator, SpeechPathology.com

SpeechPathology.com Expert eSeminar

Need assistance or technical support during event?
Please contact SpeechPathology.com at 800-242-5183

Earning CEUs

➤ Log in to your account and go to Pending Courses under the CEU Courses tab.
➤ Must pass 10-question multiple-choice exam with a score of 80% or higher
➤ Two opportunities to pass the exam
Peer Review Process

Interested in Becoming a Peer Reviewer?

APPLY TODAY!

3+ years SLP Professional Experience Required
Contact Amy Natho at anatho@speechpathology.com

Dysphagia in Neurodegenerative Disease

Focus on Amyotrophic Lateral Sclerosis & Parkinson’s Disease

Amyotrophic Lateral Sclerosis (ALS)

• "A" means no or negative.
• "Myo" refers to muscle
• "Trophic" means nourishment
  – So, “Amyotrophic” = “No muscle nourishment”
  – When a muscle has no nourishment, it "atrophy.s."
• "Lateral" identifies the areas in a person’s spinal cord where portions of the nerve cells that nourish the muscles are located.
  – As this area degenerates it leads to scarring or hardening (“sclerosis”) in the region.
ALS

- ALS involves both upper and lower motor neurons
- Presents as an idiopathic, progressive degeneration of anterior horn cells and their associated neurons resulting in progressive muscle weakness, atrophy, and fasciculations.

ALS

- There is degeneration of:
  - The lateral corticospinal tracts
  - Anterior horn cells
  - Anterior roots and peripheral nerves
  - Nuclei of cranial nerves V, VII, IX, and XII
  - Corticobulbar tracts

ALS

- Prevalence of ALS in the United States is estimated at 25,000-30,000 cases
- The incidence of ALS is two per 100,000 people.
- Approximately 5,600 people in the U.S. are diagnosed with ALS each year.
ALS

- In the United States, 90–95% of ALS cases are sporadic.
  - Military personnel are more likely to develop ALS than the general population.
- 5% are familial ALS
  - FALS is linked to a genetic defect on chromosome 9.

ALS

- Causes
  - Not completely understood.
  - Researchers and physicians suspect viruses, neurotoxins, heavy metals, DNA defects (especially in familial ALS), immune system abnormalities, and enzyme abnormalities.

ALS

- The clinical picture in all stages of ALS can vary and depends on the areas of the nervous system involved in each patient.
- Overall, the disease tends to be insidious and progressive with asymmetric weakness and atrophy.
ALS

• Three types:
  – Bulbar
    • Most rapidly progressive form
    • Involves muscles innervated by cranial nerves involved in speech and swallowing
  – Spinal
    • Progresses more slowly
    • Involves upper and lower extremities controlled by spinal nerves
  – Mixed
    • Includes symptoms of both bulbar and spinal forms

ALS Diagnosis

• Nerve conduction velocity (NCV) and electromyography (EMG) help diagnose nerve and muscle disorders.
  – NCV is administered before EMG and measures the speed at which nerves transmit electrical signals.

ALS Treatment

• There is no cure.
• Riluzole (Rilutek®) is one of the few drugs effective against ALS and may prevent progression and prolong life for a few months or so.
• Treatment focuses on relieving symptoms and maintaining an optimal quality of life.
ALS: Prognosis

- ALS is a terminal illness.
  - 50% of patients die within 3 years of diagnosis
  - 20% live 5 years
  - 10% live 10 years

ALS Severity Scale
(Hillel et al., 1989)

- Used to rate function in four areas:
  - Speech
  - Swallowing
  - Lower Extremities
  - Upper Extremities

ALS Severity Scale
(Hillel et al., 1989)

- Swallowing subscale:
  - 10 Points
    - 9-10 Normal Eating Habits
      - Normal-to-nominal abnormality
    - 7-8 Early Eating Problems
      - 8: Isolated choking episodes; regular diet
      - 7: Prolonged meal times or smaller bite size
    - 5-6 Dietary Consistency Changes
      - 6: Soft diet
      - 5: Liquefied diet
    - 3-4 Needs Tube Feeding
      - 4: Supplemental tube feedings
      - 3: Tube feeding with occasional po nutrition
    - 1-2 NPO
      - 2: Secretions managed with suction or medication or both
      - 1: Aspiration of secretions
Dysphagia in ALS

- Onset is going to vary depending upon type of ALS.
  - May be initial symptom in individuals with bulbar onset ALS.

Dysphagia in ALS

- Dysphagia management may be affected by co-occurrence of mild cognitive impairment or fronto-temporal dementia.

Dysphagia in ALS

- Speech-language pathologists often work as part of a multi-disciplinary team that may include:
  - Neurologists
  - Respiratory Therapists
  - Pulmonologists
  - Rehab Specialists: PT, OT, KT
  - Social Workers
  - Mental Health
Dysphagia in ALS

• Oral Phase Dysphagia
  – Lingual weakness is often more pronounced than jaw or lip weakness (Weikamp et al., 2012)
  • Tongue strength has been found to be a prognostic indicator of survival in ALS

Dysphagia in ALS

• Pharyngeal phase
  – Reduced laryngeal elevation
  – Reductions in pharyngeal constrictor movement
• Cervical esophageal
  – UES involvement

Dysphagia in ALS

• Initial complaints may be of occasional choking with liquids or solids.
• Individuals may complain of difficulty chewing hard, crunchy foods.
• Our role:
  – Counseling regarding safer food choices.
  – Instrumental swallow assessment if indicated.
Dysphagia in ALS

• Depending upon individual’s readiness, may discuss need to consider feeding tube placement.
  – Timing of tube placement is important
    • Weight loss of 10% or more from premorbid weight (Anderson et al., 2005)
    • Vital capacity should be >50% of predicted value (Miller et al., 2009)
  – Encourage continued p.o. intake

Dysphagia in ALS

• Individuals may complain of difficulty taking liquids from a cup
  – Many choose to use a straw instead.
  – May recommend metered dose type cup to control bolus flow and size.

Dysphagia in ALS

• Sialorrhea may be a complaint
  – Botox appears to be safe and effective.

Stokholm et al., 2013
Dysphagia in ALS

• Recommend regular follow-up with individuals
  – Our role is to continue to make recommendations for diet modifications
    • May suggest liquefying foods or adding gravies/sauces to foods
    • Suggest altering diet consistency
    • Suggest smaller meals distributed throughout the day.

Dysphagia in ALS

• Exercise-based programs
  – Very little empirical evidence that strength training improves or maintains function in the limbs
  – Some evidence that respiratory training may help maintain respiratory function
  – To date, there is no empirical evidence to support exercise-based program for treatment of dysphagia in individuals with ALS.

Parkinson’s Disease

• One million people in the U.S. have Parkinson’s Disease
• Approximately 60,000 new cases of Parkinson’s disease are diagnosed in the U.S. each year.
• The incidence of Parkinson’s disease increases with age, but 4% of cases occur before the age of 50.

  • Statistics from Parkinson’s Disease Foundation
Parkinson’s Disease
• Results from damage to the substantia nigra, which produces dopamine.
• Reduction in dopamine results in an imbalance in neurotransmitters
  – Too much acetylcholine; too little dopamine
• Characteristics include:
  – Rigidity  -Tremor
  – Bradykinesia  -Disturbed Postural Reflexes

Parkinson’s Disease
• Difficulty can occur in any phase of swallowing
  – Oral
  – Pharyngeal
  – Esophageal

Parkinson’s Disease
• Oral Phase
  – Difficulties with this phase usually occur first.
  – May include:
    • Difficulty chewing
    • Tongue pumping behavior
      – Non-propulsive back and forth motion of the tongue
    • Anterior spillage of material
    • Drooling
      – Due to reduction in frequency of swallowing
      – Up to 55% of patients with Parkinson’s report xerostomia

Tjaden, 2008
Parkinson’s Disease

• Pharyngeal Phase:
  – Delayed initiation of the pharyngeal swallow
  – Decreased tongue base retraction
  – Decreased pharyngeal contraction
  – Decreased hyolaryngeal excursion
    • Decreased airway protection during the swallow

Parkinson’s Disease

• Esophageal Phase:
  – Decreased UES opening
  – Decreased esophageal motility
  – Patients complain of feeling as if food gets stuck

Sung et al., 2010

Parkinson’s Disease

• Co-occurrence of dementia can affect swallow safety
  – Impulsivity
  – Lack of awareness of swallowing difficulty
Parkinson’s Disease

• Dysphagia Treatment
  – Lee Silverman Voice Treatment
  – Diet Modification
  – Rehabilitative Exercises
    • EMST
    • Lingual strengthening
  – Compensatory Strategies

Parkinson’s Disease

• Sialorrhea Treatment
  – Dopaminergic drugs may have some benefit
  – Botox injections to the salivary glands appear to be most effective.

Srivastchopoom et al., 2014

Conclusions

• Treatment of dysphagia in patients with neurodegenerative disease requires a unique approach and depends upon the neurological underpinnings of the disease.
• Clinicians must have a thorough understanding of the disease causing the dysphagia in order to formulate an appropriate treatment plan.